NCT02408016 · OUTCOME

Time to Progression (TTP) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria and RECIST 1.1 Mesothelioma Modified

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma · Source last updated 2021-09-13

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 3 months after last infusion

What was measured

The potential efficacy of the infused cells will be assessed and the substrate cell (TN or TCM) that is most effective based on the TTP of patients who have persisting TN cells to that of patients who have persisting TCM cells 3 months after the last infusion will be determined.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: The potential efficacy of the infused cells will be assessed and the substrate cell (TN or TCM) that is most effective based on the TTP of patients who have persisting TN cells to that of patients who have persisting TCM cells 3 months after the last infusion will be determined.
reporting Status: NOT_POSTED
time Frame: 3 months after last infusion
title: Time to Progression (TTP) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria and RECIST 1.1 Mesothelioma Modified
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice